TOP TEN perturbations for 38589_i_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38589_i_at
Selected probe(set): 200772_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38589_i_at (200772_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
glioma study 16 (LN-18) / normal astrocyte sample
Relative Expression (log2-ratio):3.4559832Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-18) |
| Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
glioma study 16 (LN-229) / normal astrocyte sample
Relative Expression (log2-ratio):3.4172754Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-229) |
| Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
glioma study 16 (BS-149) / normal astrocyte sample
Relative Expression (log2-ratio):3.2519884Number of Samples:2 / 3
| Experimental | glioma study 16 (BS-149) |
| Human glioma cell line BS149 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
pediatric septic shock study 3 (infant; subclass A) / pediatric septic shock study 3 (infant)
Relative Expression (log2-ratio):-2.975481Number of Samples:8 / 30
| Experimental | pediatric septic shock study 3 (infant; subclass A) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | pediatric septic shock study 3 (infant) |
| Whole blood obtained from infants (1 month – 1 year) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Five children did not survive. |
myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.818944Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM-like) |
| Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)
Relative Expression (log2-ratio):-2.5530787Number of Samples:8 / 17
| Experimental | pediatric septic shock study 3 (infant; subclass A) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | normal blood sample (infant) |
| Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study. |
glioma study 16 (LN-319) / normal astrocyte sample
Relative Expression (log2-ratio):2.512166Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-319) |
| Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
glioma study 16 (LN-215) / normal astrocyte sample
Relative Expression (log2-ratio):2.445157Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-215) |
| Human glioma cell line LN215 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
IFN-g; LPS study 1 / normal resting monocyte sample
Relative Expression (log2-ratio):-2.3345928Number of Samples:2 / 2
| Experimental | IFN-g; LPS study 1 |
| Monocytes LPS/IFN-g activated for 30h. | |
| Control | normal resting monocyte sample |
| Monocytes resting for 30h. |
myotonic dystrophy study 4 (skeletal muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.271411Number of Samples:8 / 3
| Experimental | myotonic dystrophy study 4 (skeletal muscle; DM2) |
| Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
Organism: Homo sapiens
Gene: 38589_i_at
Selected probe(set): 216515_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38589_i_at (216515_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
glioma study 16 (LN-229) / normal astrocyte sample
Relative Expression (log2-ratio):2.1601543Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-229) |
| Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
glioma study 16 (BS-149) / normal astrocyte sample
Relative Expression (log2-ratio):2.0898323Number of Samples:2 / 3
| Experimental | glioma study 16 (BS-149) |
| Human glioma cell line BS149 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
glioma study 16 (LN-18) / normal astrocyte sample
Relative Expression (log2-ratio):2.0244827Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-18) |
| Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample
Relative Expression (log2-ratio):-1.7833652Number of Samples:3 / 3
| Experimental | kidney transplantation study 16 (2 week) |
| CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
| Control | normal natural killer cell (CD56+) sample |
| CD56+ natural killer cell samples derived from healthy control subjects. |
myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.6794052Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM-like) |
| Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (skeletal muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.6552773Number of Samples:8 / 3
| Experimental | myotonic dystrophy study 4 (skeletal muscle; DM2) |
| Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (biceps brachii; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.6285686Number of Samples:9 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM-like) |
| Biceps brachii biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (deltoid muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.5889626Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM2) |
| Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
glioma study 16 (LN-319) / normal astrocyte sample
Relative Expression (log2-ratio):1.5713129Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-319) |
| Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
IFN-g; LPS study 1 / normal resting monocyte sample
Relative Expression (log2-ratio):-1.5117311Number of Samples:2 / 2
| Experimental | IFN-g; LPS study 1 |
| Monocytes LPS/IFN-g activated for 30h. | |
| Control | normal resting monocyte sample |
| Monocytes resting for 30h. |
Organism: Homo sapiens
Gene: 38589_i_at
Selected probe(set): 216384_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38589_i_at (216384_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):2.1620913Number of Samples:11 / 6
| Experimental | ovarian tumor study 11 (low grade) |
| Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. | |
| Control | normal ovarian surface epithelial cell sample |
| Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals. |
myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.057704Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM-like) |
| Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
pediatric septic shock study 3 (infant; subclass A) / pediatric septic shock study 3 (infant)
Relative Expression (log2-ratio):-1.8108664Number of Samples:8 / 30
| Experimental | pediatric septic shock study 3 (infant; subclass A) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | pediatric septic shock study 3 (infant) |
| Whole blood obtained from infants (1 month – 1 year) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Five children did not survive. |
keratinocyte differentiation study 2 (KLF4 siRNA) / keratinocyte differentiation study 2
Relative Expression (log2-ratio):1.7370682Number of Samples:2 / 2
| Experimental | keratinocyte differentiation study 2 (KLF4 siRNA) |
| KLF4 (Kruppel-like factor 4) depleted primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. KLF4 depletion was done using siRNAs: KLF4i(A): CCGAGGAGTTCAACGATCT; KLF4i(B): TGACCAGGCACTACCGTAA. Differentiation was induced at 100% confluency. | |
| Control | keratinocyte differentiation study 2 |
| Primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. Differentiation was induced at 100% confluency. |
myotonic dystrophy study 4 (biceps brachii; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.7071447Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM2) |
| Biceps brachii biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (skeletal muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.6877556Number of Samples:8 / 3
| Experimental | myotonic dystrophy study 4 (skeletal muscle; DM2) |
| Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (biceps brachii; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.6843462Number of Samples:9 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM-like) |
| Biceps brachii biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
IFN-g; LPS study 1 / normal resting monocyte sample
Relative Expression (log2-ratio):-1.6817303Number of Samples:2 / 2
| Experimental | IFN-g; LPS study 1 |
| Monocytes LPS/IFN-g activated for 30h. | |
| Control | normal resting monocyte sample |
| Monocytes resting for 30h. |
atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):1.6670885Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (lesional; whole skin) |
| Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
myotonic dystrophy study 4 (deltoid muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.6112423Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM2) |
| Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
Organism: Homo sapiens
Gene: 38589_i_at
Selected probe(set): 216384_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38589_i_at (216384_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):2.1620913Number of Samples:11 / 6
| Experimental | ovarian tumor study 11 (low grade) |
| Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. | |
| Control | normal ovarian surface epithelial cell sample |
| Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals. |
myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.057704Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM-like) |
| Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
pediatric septic shock study 3 (infant; subclass A) / pediatric septic shock study 3 (infant)
Relative Expression (log2-ratio):-1.8108664Number of Samples:8 / 30
| Experimental | pediatric septic shock study 3 (infant; subclass A) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | pediatric septic shock study 3 (infant) |
| Whole blood obtained from infants (1 month – 1 year) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Five children did not survive. |
keratinocyte differentiation study 2 (KLF4 siRNA) / keratinocyte differentiation study 2
Relative Expression (log2-ratio):1.7370682Number of Samples:2 / 2
| Experimental | keratinocyte differentiation study 2 (KLF4 siRNA) |
| KLF4 (Kruppel-like factor 4) depleted primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. KLF4 depletion was done using siRNAs: KLF4i(A): CCGAGGAGTTCAACGATCT; KLF4i(B): TGACCAGGCACTACCGTAA. Differentiation was induced at 100% confluency. | |
| Control | keratinocyte differentiation study 2 |
| Primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. Differentiation was induced at 100% confluency. |
myotonic dystrophy study 4 (biceps brachii; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.7071447Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM2) |
| Biceps brachii biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (skeletal muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.6877556Number of Samples:8 / 3
| Experimental | myotonic dystrophy study 4 (skeletal muscle; DM2) |
| Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (biceps brachii; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.6843462Number of Samples:9 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM-like) |
| Biceps brachii biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
IFN-g; LPS study 1 / normal resting monocyte sample
Relative Expression (log2-ratio):-1.6817303Number of Samples:2 / 2
| Experimental | IFN-g; LPS study 1 |
| Monocytes LPS/IFN-g activated for 30h. | |
| Control | normal resting monocyte sample |
| Monocytes resting for 30h. |
atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):1.6670885Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (lesional; whole skin) |
| Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
myotonic dystrophy study 4 (deltoid muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.6112423Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM2) |
| Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
Organism: Homo sapiens
Gene: 38589_i_at
Selected probe(set): 211921_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38589_i_at (211921_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.663331Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM-like) |
| Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
pediatric septic shock study 3 (infant; subclass A) / pediatric septic shock study 3 (infant)
Relative Expression (log2-ratio):-2.6392689Number of Samples:8 / 30
| Experimental | pediatric septic shock study 3 (infant; subclass A) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | pediatric septic shock study 3 (infant) |
| Whole blood obtained from infants (1 month – 1 year) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Five children did not survive. |
IFN-g; LPS study 1 / normal resting monocyte sample
Relative Expression (log2-ratio):-2.5516691Number of Samples:2 / 2
| Experimental | IFN-g; LPS study 1 |
| Monocytes LPS/IFN-g activated for 30h. | |
| Control | normal resting monocyte sample |
| Monocytes resting for 30h. |
pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)
Relative Expression (log2-ratio):-2.3396435Number of Samples:8 / 17
| Experimental | pediatric septic shock study 3 (infant; subclass A) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | normal blood sample (infant) |
| Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study. |
myotonic dystrophy study 4 (deltoid muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.2618809Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM2) |
| Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (skeletal muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.193902Number of Samples:8 / 3
| Experimental | myotonic dystrophy study 4 (skeletal muscle; DM2) |
| Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (biceps brachii; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.1649303Number of Samples:9 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM-like) |
| Biceps brachii biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):2.1338415Number of Samples:11 / 6
| Experimental | ovarian tumor study 11 (low grade) |
| Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. | |
| Control | normal ovarian surface epithelial cell sample |
| Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals. |
myotonic dystrophy study 4 (biceps brachii; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.005372Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM2) |
| Biceps brachii biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-1.9937468Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA contr.) |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated / transduced MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
Organism: Homo sapiens
Gene: 38589_i_at
Selected probe(set): 211921_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38589_i_at (211921_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.663331Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM-like) |
| Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
pediatric septic shock study 3 (infant; subclass A) / pediatric septic shock study 3 (infant)
Relative Expression (log2-ratio):-2.6392689Number of Samples:8 / 30
| Experimental | pediatric septic shock study 3 (infant; subclass A) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | pediatric septic shock study 3 (infant) |
| Whole blood obtained from infants (1 month – 1 year) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Five children did not survive. |
IFN-g; LPS study 1 / normal resting monocyte sample
Relative Expression (log2-ratio):-2.5516691Number of Samples:2 / 2
| Experimental | IFN-g; LPS study 1 |
| Monocytes LPS/IFN-g activated for 30h. | |
| Control | normal resting monocyte sample |
| Monocytes resting for 30h. |
pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)
Relative Expression (log2-ratio):-2.3396435Number of Samples:8 / 17
| Experimental | pediatric septic shock study 3 (infant; subclass A) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | normal blood sample (infant) |
| Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study. |
myotonic dystrophy study 4 (deltoid muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.2618809Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM2) |
| Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (skeletal muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.193902Number of Samples:8 / 3
| Experimental | myotonic dystrophy study 4 (skeletal muscle; DM2) |
| Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (biceps brachii; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.1649303Number of Samples:9 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM-like) |
| Biceps brachii biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):2.1338415Number of Samples:11 / 6
| Experimental | ovarian tumor study 11 (low grade) |
| Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. | |
| Control | normal ovarian surface epithelial cell sample |
| Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals. |
myotonic dystrophy study 4 (biceps brachii; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.005372Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM2) |
| Biceps brachii biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-1.9937468Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA contr.) |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated / transduced MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
Organism: Homo sapiens
Gene: 38589_i_at
Selected probe(set): 211921_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38589_i_at (211921_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.663331Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM-like) |
| Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
pediatric septic shock study 3 (infant; subclass A) / pediatric septic shock study 3 (infant)
Relative Expression (log2-ratio):-2.6392689Number of Samples:8 / 30
| Experimental | pediatric septic shock study 3 (infant; subclass A) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | pediatric septic shock study 3 (infant) |
| Whole blood obtained from infants (1 month – 1 year) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Five children did not survive. |
IFN-g; LPS study 1 / normal resting monocyte sample
Relative Expression (log2-ratio):-2.5516691Number of Samples:2 / 2
| Experimental | IFN-g; LPS study 1 |
| Monocytes LPS/IFN-g activated for 30h. | |
| Control | normal resting monocyte sample |
| Monocytes resting for 30h. |
pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)
Relative Expression (log2-ratio):-2.3396435Number of Samples:8 / 17
| Experimental | pediatric septic shock study 3 (infant; subclass A) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | normal blood sample (infant) |
| Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study. |
myotonic dystrophy study 4 (deltoid muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.2618809Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM2) |
| Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (skeletal muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.193902Number of Samples:8 / 3
| Experimental | myotonic dystrophy study 4 (skeletal muscle; DM2) |
| Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (biceps brachii; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.1649303Number of Samples:9 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM-like) |
| Biceps brachii biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):2.1338415Number of Samples:11 / 6
| Experimental | ovarian tumor study 11 (low grade) |
| Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. | |
| Control | normal ovarian surface epithelial cell sample |
| Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals. |
myotonic dystrophy study 4 (biceps brachii; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.005372Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM2) |
| Biceps brachii biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-1.9937468Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA contr.) |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated / transduced MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |